Zhi Tong Cai Jing·2025-07-29 03:39Group 1 - CRO concept stocks showed strong performance in early trading, with WuXi AppTec (药明康德) rising by 9.66% to HKD 110.1, Tigermed (泰格医药) up 8.14% to HKD 57.8, and others also experiencing significant gains [1] - WuXi AppTec reported a revenue of RMB 20.799 billion for the first half of 2025, a year-on-year increase of 20.6%, and a net profit attributable to shareholders of RMB 8.287 billion, up 95.5% year-on-year [1] - The company announced an upward revision of its full-year performance guidance, expecting a revenue range of RMB 42.5-43.5 billion, with a growth rate adjustment from 10-15% to 13-17% [1] Group 2 - Everbright Securities indicated that the CXO sector is gradually emerging from a low point, with several companies showing signs of recovery, supported by favorable factors such as potential interest rate cuts by the Federal Reserve and improved financing conditions in the pharmaceutical sector [2] - Zhongtai Securities noted that the CRO and CDMO sectors are expected to see a gradual recovery in demand due to multiple catalysts, including the onset of overseas interest rate cuts in Q4 2024 and significant policy developments in 2025 [2] - The sector is anticipated to experience a "Davis Double Play" with simultaneous improvements in profitability and valuation, suggesting a focus on investment opportunities within this space [2]